Building on positive clinical data from Topas' Phase 1 study of TPM203 in pemphigus vulgaris patients, the Phase 2a study in celiac disease patients initiates clinical development for TPM502 and
Merck invests ⬠250M in new biotech development centre in Switzerland
Merck invests ⬠250M in new biotech development centre in Switzerland 07 July 2021 | News
image credit- businesswire
German firm Merck has announced the topping-out ceremony for its new Biotech Development Center in Corsier-sur-Vevey, Switzerland.
This investment of € 250 million, which was announced in January 2020, is intended to help secure the capacities for a cost-efficient and agile provision of clinical study medication in the long term, to shorten the development time of novel biological active ingredients and to meet the challenge of the increasingly complex production of biotechnological substances to master the next generation.
Merck Celebrates Key Milestone in Construction of Biotech Development Center in Switzerland finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.